XERS
Price
$4.58
Change
+$0.12 (+2.69%)
Updated
Jun 6 closing price
Capitalization
714.29M
59 days until earnings call
XNCR
Price
$9.65
Change
+$0.53 (+5.81%)
Updated
Jun 6 closing price
Capitalization
649.08M
52 days until earnings call
Interact to see
Advertisement

XERS vs XNCR

Header iconXERS vs XNCR Comparison
Open Charts XERS vs XNCRBanner chart's image
Xeris Biopharma Holdings
Price$4.58
Change+$0.12 (+2.69%)
Volume$1.82M
Capitalization714.29M
Xencor
Price$9.65
Change+$0.53 (+5.81%)
Volume$526.02K
Capitalization649.08M
XERS vs XNCR Comparison Chart
Loading...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
XERS vs. XNCR commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XERS is a StrongBuy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (XERS: $4.78 vs. XNCR: $7.55)
Brand notoriety: XERS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: XERS: 50% vs. XNCR: 59%
Market capitalization -- XERS: $714.29M vs. XNCR: $649.08M
XERS [@Biotechnology] is valued at $714.29M. XNCR’s [@Biotechnology] market capitalization is $649.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XERS’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • XERS’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both XERS and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XERS’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • XERS’s TA Score: 4 bullish, 5 bearish.
  • XNCR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than XERS.

Price Growth

XERS (@Biotechnology) experienced а -2.85% price change this week, while XNCR (@Biotechnology) price change was +0.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

XERS is expected to report earnings on Aug 06, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($714M) has a higher market cap than XNCR($649M). XERS YTD gains are higher at: 41.003 vs. XNCR (-67.145). XERS has higher annual earnings (EBITDA): -13.99M vs. XNCR (-186.17M). XNCR has more cash in the bank: 498M vs. XERS (71.6M). XNCR has less debt than XERS: XNCR (232M) vs XERS (271M). XERS has higher revenues than XNCR: XERS (203M) vs XNCR (110M).
XERSXNCRXERS / XNCR
Capitalization714M649M110%
EBITDA-13.99M-186.17M8%
Gain YTD41.003-67.145-61%
P/E RatioN/AN/A-
Revenue203M110M185%
Total Cash71.6M498M14%
Total Debt271M232M117%
FUNDAMENTALS RATINGS
XERS vs XNCR: Fundamental Ratings
XERS
XNCR
OUTLOOK RATING
1..100
724
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3795
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (79) in the Biotechnology industry is in the same range as XERS (91) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to XERS’s over the last 12 months.

XERS's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as XNCR (100) in the Biotechnology industry. This means that XERS’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (95) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for XERS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew significantly faster than XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XERSXNCR
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
80%
Bullish Trend 12 days ago
73%
Momentum
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 12 days ago
77%
MACD
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 12 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
79%
Bearish Trend 12 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
87%
Bearish Trend 12 days ago
84%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 25 days ago
71%
Declines
ODDS (%)
Bearish Trend 18 days ago
82%
Bearish Trend about 1 month ago
81%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
84%
Bullish Trend 12 days ago
76%
Aroon
ODDS (%)
Bullish Trend 12 days ago
85%
Bearish Trend 12 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-1.04%
TRDA - XERS
51%
Loosely correlated
+0.91%
XNCR - XERS
48%
Loosely correlated
-2.58%
KRYS - XERS
46%
Loosely correlated
-2.44%
CGON - XERS
45%
Loosely correlated
-0.94%
YMAB - XERS
45%
Loosely correlated
+4.76%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with RCKT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-2.58%
RCKT - XNCR
59%
Loosely correlated
+6.44%
CRNX - XNCR
58%
Loosely correlated
+1.39%
ERAS - XNCR
57%
Loosely correlated
+1.85%
BEAM - XNCR
57%
Loosely correlated
-0.88%
BCYC - XNCR
54%
Loosely correlated
+2.12%
More